Modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 1035-1040

  Pluschnig, Ursula ^a   Schoppmann, Sebastian F ^a   Preusser, Matthias ^a   Datler, Philip ^a   Asari, Reza ^a   Ba Ssalamah, Ahmed ^a   Schwameis, Katrin ^a   Birner, Peter ^a   Zacherl, Johannes ^a   Hejna, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Adenocarcinoma; Capecitabine; Epirubicin; Gastroesophageal cancer; Oxaliplatin

Indexed keywords

CAPECITABINE; EPIRUBICIN; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS CARCINOMA; FATIGUE; FEMALE; GASTROESOPHAGEAL ADENOCARCINOMA; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMACH CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; VENOUS THROMBOEMBOLISM; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; EPIRUBICIN; ESOPHAGOGASTRIC JUNCTION; FEMALE; FLUOROURACIL; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PALLIATIVE CARE; STOMACH NEOPLASMS;

EID: 84875911759     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bertuccio P, Chatenoud L, Levi F, Proud D, Ferlay J, Negri E, Malvezzi M and La Vecchia C: Recent Pattern in gastric cancer: A global overview. Int J Cancer 125: 666-673, 2009.
2. Malvezzi M, Arfe A, Bertuccio P, Levi F, La Vecchia C and Negri E: European cancer mortality predictions for the year 2011. Ann Oncol 22: 947-956, 2011.
3. Wagner AD, Groethe W, Haerting J, Kleber G, Grothey A and Fleig WE: Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data. J Clin Oncol 24: 2903-2909, 2006.
4. Murad AM, Santiago FF and Petrioianu A: Modified therapy with 5-fluorouracil, doxorubicin and methotrexate in advanced gastric cancer. Cancer 72: 37-41, 1993.
5. Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomized comparison of fluorouracil, epirubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with nonresectable gastric cancer. Br J Cancer 71: 587-591, 1995.
6. Glimelius B, Ekstrom K, Hoffman K, Graf W, Sjoden PO, Haglund U, Svensson C, Enander LK, Linne T, Sellstrom H and Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163-168, 1997.
7. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML and Ajani J: A Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first line treatment for advanced gastric cancer: A Report of the V325 study group. J Clin Oncol 24: 4991-4997, 2006.
8. Bojic M, Pluschnig U, Zacherl J, Thallinger CM, Ba-Ssalamah A, Maresch J, Datler P, Schoppmann SF and Hejna M: Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colonystimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: Experience at the Medical University of Vienna. Anticancer Res 31: 2379-2382, 2011.
9. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Oates J and Norman AR: Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36-44, 2008.
10. Al Batran SE, Hartmann JT, Hofheinz R, Homann N, Rathwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A and Jager E: Biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel for patients with metastatic adenocarcinoma of tue stomach ob esophagogastric junction: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Ann Oncol 19: 1882-1887, 2008.
11. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 376: 687-697, 2010.
12. US Department of Health and Human Services; National Institutes of Health; National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 4.03: NIH Publication No. 09-5410, 2010.
13. Miller AB, Hoogstraten B, Staquet M and Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
14. Siewert JR, Stein HJ and Feith M: Adenocarcinoma of the esophago-gastric junction. Scand J Surg 95: 260-269, 2006.